Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
5363
NVO
Novo Nordisk A/S
49.28 USD-0.40%-2.01%+10.22%-29.02%0 USD
5579
CELG-RT
Bristol-Myers Squibb Company Celegne Contingent Value Rights
0.1184 USD0.00%+0.85%-3.74%+273.50%0 USD
6419
AADI
Aadi Bioscience Inc
2.05 USD0.00%0.00%-19.29%-27.30%0 USD
6552
RVMDW
Revolution Medicines, Inc. - Warrant
8.9700 USD-4.17%-5.28%+50.76%+3488.00%39.11 B USD

Frequently asked questions about Adaptimmune Therapeutics plc - American Depositary Shares

What is the Adaptimmune Therapeutics plc - American Depositary Shares stock price today?

The current price of Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) is 0.05. Over the past 24 hours, the stock has changed by 0.00%. Follow the ADAP chart for real-time price dynamics.

What is the stock ticker of Adaptimmune Therapeutics plc - American Depositary Shares?

Adaptimmune Therapeutics plc - American Depositary Shares trades under the ticker ADAP. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

How many employees does Adaptimmune Therapeutics plc - American Depositary Shares have?

As of the latest available data, Adaptimmune Therapeutics plc - American Depositary Shares has 506 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Adaptimmune Therapeutics plc - American Depositary Shares stock?

You can buy Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Adaptimmune Therapeutics plc - American Depositary Shares stock?

Investing in Adaptimmune Therapeutics plc - American Depositary Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ADAP chart and related analysis on metatrader.com as part of your research.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor.

News